ScholarIQanswers from OpenAlex & ORCID
Michael A. Nauck
ResearcherPublications, citations & collaboration network
Michael A. Nauck is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael A. Nauck have?
ScholarIQindexed works
Michael A. Nauck has 587 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael A. Nauck have?
ScholarIQcitation count
Michael A. Nauck has 67,741 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael A. Nauck?
ScholarIQh-index
Michael A. Nauck has an h-index of 112 in OpenAlex.
What is the i10-index of Michael A. Nauck?
ScholarIQi10-index
Michael A. Nauck has an i10-index of 315 in OpenAlex.
What is the ORCID of Michael A. Nauck?
ScholarIQorcid
The ORCID for Michael A. Nauck is on the source record.
What is the OpenAlex record for Michael A. Nauck?
ScholarIQopenalex
The OpenAlex for Michael A. Nauck is on the source record.
What are the most-cited papers on Michael A. Nauck?
ScholarIQmost cited works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Lasse Steen Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaëla Diamant, Ele Ferrannini, Michael A. Nauck, Anne L. Peters, Απόστολος Τσάπας, Richard C. Wender, David R. Matthews
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse, Michaëla Diamant, Ele Ferrannini, Michael A. Nauck, Anne L. Peters, Απόστολος Τσάπας, Richard C. Wender, David R. Matthews
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel C. Jones, Lawrence A. Leiter, Anne E Rosenberg, Kristina N. Sigmon, Matthew C. Somerville, Karl M. Thorpe, John J.V. McMurray, Stefano Del Prato, Stefano Del Prato, John J.V. McMurray, Ralph B. D’Agostino, Christopher B. Granger, Adrian F. Hernandez, Salim Janmohamed, Lawrence A. Leiter, Robert M. Califf, Rury R. Holman, David L. DeMets, Matthew C. Riddle, Shaun G. Goodman, Darren K. McGuire, Karen Alexander, Adam D. DeVore, Chiara Melloni, Chetan B. Patel, David C. M. Kong, Gerald S. Bloomfield, Matthew T. Roe, Pierluigi Tricoci, Robert W. Harrison, Renato D. Lópes, Robin Mathews, Rajendra Mehta, W. Schuyler Jones, Sreekanth Vemulapalli, Thomas J. Povsic, Zubin J. Eapen, Keith Dombrowski, Brad J. Kolls, J. Dedrick Jordan, Andrew P. Ambrosy, Stephen J. Greene, Aditya Mandawat, Jay Shavadia, Lauren B. Cooper, Abhinav Sharma, Patrícia O. Guimarães, Daniel J. Friedman, Matthew E. Wilson, Patricia Endsley, Tracy Gentry, Jeannie Collier, Kathleen Perez, K.E. James, Jennifer Roush, C. ARDEN III POPE, Christina Howell, Megan Johnson, M. Bailey, Joanna Cole, Teresa Akers, Beth Vandyne, Betsy Thomas, Jenny Rich, Susan Bartone, Gail Beaulieu, Kim Brown, Tuan Chau, Tamra Christian, Rebecca Coker, Deb Greene, Trevorlyn Haddock, Wendy Jenkins, Ghazala Haque, Marsha L. Marquess, Jean Pesarchick, Renee Rethaford, Allegra Stone, Firas Al- Kawas, Michelle A. Anderson, Robert Enns, Isaac Sinay, Chantal Mathieu, Victor Yordanov, Irene Hramiak, Martin Haluzı́k, Søren Galatius, Bruno Guerci, Michael A. Nauck, Ilias Migdalis, Choon Beng Kathryn Tan, Győző Kocsis, Andrea Giaccari, Moon Kyu Lee, Ernesto Muñoz
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E. Gimeno, Zvonko Miličević, Deborah A. Robins, Axel Haupt